TLR2 and hyperlipidemia: In contrast, our results demonstrated that hepatic PCSK9 knockdown or inhibition particularly reduced TLR-2 level rather than TLR-4 level, with inhibition of the downstream NF-κB and AP-1 signaling pathways, thus suggesting PCSK9 suppression may stimulate different TLR family members following hyperlipidemia challenge.